post

CAR-T cell therapy in myeloma

Research news // 21st December 2017

CAR-T cell therapy (adoptive T cell transfer) is an exciting area of research and represents an entirely new way of killing myeloma cells compared to current ways of treating myeloma. We’ve put together this suite of information to help you understand this potential new treatment.Much research is underway looking at how the body’s own immune system can be harnessed to kill myeloma cells. Adoptive T cell transfer is a new treatment that does this by collecting T cells (a type of white blood cell that makes up part of the immune system) from a patient’s blood, genetically modifying them in the laboratory to boost their ability to recognise and kill myeloma cells, then giving them back to the patient.

You can read more about how this treatment works in the newest Infosheet in our Horizons series, Adoptive T cell transfer Horizons Infosheet.

One way of modifying T cells involves adding receptors to form chimeric antigen receptor T cells (CAR-T cells). These have shown the most promise in treating myeloma and are currently being investigated in trials. This quarter’s edition of Myeloma Matters features a Q&A about CAR-T cell therapy (page 16) with Dr Rakesh Popat, Consultant Haematologist at University College Hospital, London.

You can find the whole magazine available to download and/or sign up to here.

You can also find out more about adoptive T cell transfer by watching Dr Martin Kaiser, Senior Research Fellow at the Institute of Cancer Research, discuss new treatment strategies in myeloma in the video below.

If you have any more questions regarding CAR-T cell therapy, call our Myeloma Infoline on 0800 980 3332 or e-mail your questions to AskTheNurse@myeloma.org.uk.

Leave a comment on this story:

Comments are closed.